Pfizer Pharmaceuticals of the United States and BioNTech of Germany announced the first batch of results of their phase III clinical trials of the new crown vaccine before the U.S. stock market, showing that its effectiveness exceeds 90%

The US company conducted Phase III clinical trials with the largest number of participants. On September 16, it recruited 30,000 people and later expanded to 44,000 people. Among them, 42% of global participants and 30% of US participants All have different ethnic backgrounds.

Among them, only 164 confirmed cases were analyzed. In the interim analysis of the data, 4,300 received 2 doses of vaccine or placebo. The interval between two injections of the reagent is only 21 days, and the observation period is one week after receiving the vaccine. On this basis, 94 participants were studied.

The effectiveness of this vaccine experiment has greatly exceeded the 50% standard set by the United States, and at the same time, it has also exceeded the expectations of Pfizer and BioNTech (60%-70%).